Carcinoid Syndrome
📧 Sign up to get email alerts when something new happens for Carcinoid Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2013-07-26Clinical Trial Update: Study of Panitumumab in the Treatment of Carcinoid Syndrome [Phase 2]
A Phase 2 study of panitumumab for carcinoid syndrome sponsored by Boston Medical Center has been withdrawn.
-
FDA approval · 2013-05-23FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Octreotide acetate submitted by Mylan Institutional LLC.
-
FDA approval · 2012-09-12FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for octreotide acetate (ANDA) by Hikma Pharmaceuticals USA Inc. The approval updates the labeling or…
-
FDA approval · 2012-06-28FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals, Inc.)
The FDA approved a supplemental application for octreotide acetate from Meitheal Pharmaceuticals, authorizing a generic version of the drug.…
-
CLINICAL_TRIALS trial_result · 2012-06-15Clinical Trial Update: Effects of Serotonin Excess on Bone in Carcinoid Syndrome
A completed clinical trial investigated how serotonin excess affects bone health in patients with carcinoid syndrome.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-03-12Clinical Trial Update: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor [Phase 3]
A Phase 3 trial evaluating the combination of everolimus and octreotide in patients with advanced carcinoid tumor has completed and posted r…
-
FDA label_change · 2011-09-30FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation, involving cha…
-
FDA approval · 2011-02-10FDA Approved: OCTREOTIDE ACETATE — Original Application (Mylan Institutional LLC)
The FDA approved the original ANDA for octreotide acetate from Mylan Institutional LLC. This marks the generic approval for this product.
-
FDA approval · 2009-03-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for octreotide acetate submitted by Hikma Pharmaceuticals USA Inc., under the ANDA pathway.